1993
Use of the Magnetic Resonance Contrast Agent Gadodiamide in the Central Nervous System Results of a Multicenter Trial
SZE G, BRANT-ZAWADZKI M, McNAMARA M, HAUGHTON V, KUMAR A, MARAVILLA K, AISEN A, DREISBACH J, BRADLEY W, WEINREB J, DRAYER B, TSURUDA J, HESSELINK J, JOHNSON C, ZIMMERMAN R, WEINGAST G. Use of the Magnetic Resonance Contrast Agent Gadodiamide in the Central Nervous System Results of a Multicenter Trial. Investigative Radiology 1993, 28: s49-s55. PMID: 8486504, DOI: 10.1097/00004424-199303001-00006.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingPhase II/III clinical trialsVital signsCentral nervous system resultsSignificant adverse eventsNervous system resultsNonionic contrast agentsVisualization of lesionsPreinjection imagesAdverse eventsNeurologic statusMulticenter trialClinical statusMulticenter studyClinical trialsPatient's vital signsMRI scansGadodiamide injectionPatientsResonance imagingSafety parametersContrast enhancementInjectionTrialsSpine
1992
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
Rofsky N, Weinreb J. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent. Magnetic Resonance Quarterly 1992, 8: 156-68. PMID: 1390058.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMn-DPDPN'-dipyridoxylethylenediamineClinical experienceNon-enhanced T1Significant adverse eventsEnhanced magnetic resonance imagingManganese NT2-weighted imagesAdverse eventsHepatocellular originClinical trialsContrast agentsHepatobiliary agentsResonance imagingLiver imagingFavorable resultsLesion detectionNew contrast agentsIssues of safetyImaging techniquesAgentsImagingOptimal methodNumerous strategies